Posted on December 10th, 2008 by Health News
(MDS Foundation) The Myelodysplastic Syndromes Foundation announced today that data presented at this year’s American Society of Hematology Meeting in San Francisco demonstrate that patients with acute myeloid leukemia who were treated with vidaza (azacitidine) had significantly increased overall survival compared to those treated with conventional care regimens.
No Comments »
Filed under: General Health News
Posted on December 10th, 2008 by Health News
(MDS Foundation) The Myelodysplastic Syndromes Foundation announced today that a new analysis of the AZA-001 phase III clinical trial demonstrates that continued treatment with vidaza (azacitidine) can improve response rates for higher-risk MDS patients.
No Comments »
Filed under: General Health News
Posted on December 10th, 2008 by Health News
(MDS Foundation) The Myelodysplastic Syndromes Foundation announced today that a subanalysis of the AZA-001 phase III international clinical trial shows that treatment with vidaza can extend overall survival and reduce the risk of death in elderly higher-risk MDS patients.
No Comments »
Filed under: General Health News
Posted on December 10th, 2008 by Health News
(Celgene International Sàrl) Celgene International Sarl announced that data from a landmark analysis of patients with relapsed/refractory multiple myeloma found that continuous treatment with revlimid in combination with dexamethasone after achieving best response resulted in significantly longer overall survival, and increased time to disease progression compared to those who discontinued treatment after 10 months or [...]
No Comments »
Filed under: General Health News
Posted on December 10th, 2008 by Health News
(Celgene International Sàrl) Celgene International Sarl today announced that its next IMiDs compound, pomalidomide, has shown promising activity with manageable safety and tolerability for the treatment of relapsed/refractory multiple myeloma and myelofibrosis. The data were presented at the 50th Annual American Society of Hematology meeting in San Francisco.
No Comments »
Filed under: General Health News
Posted on December 10th, 2008 by Health News
(Celgene International Sàrl) Celgene International Sarl reported that results of a phase I study presented today combining revlimid and vidaza in patients with higher-risk myelodysplastic syndromes found that the combination of these two therapies is well tolerated and has high activity. The data was reported during the 50th Annual Meeting of the American Society of [...]
No Comments »
Filed under: General Health News
Posted on December 10th, 2008 by Health News
(Celgene International Sàrl) Celgene International Sarl today announced more mature data from clinical studies of revlimid (lenalidomide) in newly-diagnosed multiple myeloma were presented at a joint symposium of the American Society of Clinical Oncology and the American Society of Hematology on Sunday, Dec. 7. The results from the ECOG E4A03 study of revlimid plus low-dose [...]
No Comments »
Filed under: General Health News
Posted on December 10th, 2008 by Health News
(Celgene International Sàrl) Celgene International Sarl and the Groupe d’Etude des Lymphomes de l’Adulte today announced the initiation of an international randomized, double-blind, controlled Phase III study to evaluate the therapeutic potential of revlimid as a maintenance therapy for elderly, high-risk patients with diffuse large B-cell lymphoma who have responded to standard first line rituximab, [...]
No Comments »
Filed under: General Health News
Posted on December 10th, 2008 by Health News
(Hebrew SeniorLife Institute for Aging Research) Deaths due to dementia and Alzheimer’s disease are underreported on death certificates, according to a study conducted by Hebrew SeniorLife’s Institute for Aging Research, raising concerns about the accuracy of mortality statistics based on these documents.
No Comments »
Filed under: General Health News
Posted on December 10th, 2008 by Health News
(Medical College of Georgia) Children with diabetes are at an increased risk for developing eating disorders, and researchers want to know if it’s their disease or treatment that’s to blame.
No Comments »
Filed under: General Health News
